Changes in immune cell counts and interleukin (IL)-1beta production in humans after a somnogenically active growth hormone-releasing hormone (GHRH) administration.
Growth hormone-releasing hormone (GHRH) has been shown to enhance slow-wave sleep (SWS) and non-rapid eye movement sleep in animals and humans. In animals the somnogenic effect of interleukin (IL)-1beta appears to be mediated by GHRH. Neuroimmunological interactions in sleep are most frequently studied in humans by sleep deprivation or by cytokine administration. The present study, in contrast, investigates in humans the effect of enhanced sleep through GHRH administration on selected immune parameters. Results reveal that a single intravenous bolus of 50 microg GHRH which enhanced SWS stage 4 in the first half of the night suppressed circulating suppressor T cell (CD3+/CD8+) numbers, with a similar tendency for B cells (CD19+) and suppressed mitogen-stimulated IL-1beta production. When the same amount of GHRH was administered distributed across five repetitive boluses of 10 microg GHRH within 1 h, neither corresponding sleep nor immune parameters were changed significantly compared to placebo. These data suggest that GHRH can modulate immune functions through brain mechanisms which are also involved in the regulation of sleep.
Marshall
L
L
Clinical Neuroendocrinology, Medical University of Luebeck, D-23538 Luebeck, Germany.
Perras
B
B
Fehm
H L
HL
Born
J
J
D000328:Adult; D002452:Cell Count; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D006801:Humans; D007107:Immune System / Q000166:cytology* / Q000187:drug effects*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D008297:Male; D012890:Sleep / Q000187:drug effects*; D012894:Sleep Stages / Q000187:drug effects; D013997:Time Factors
D007375:Interleukin-1; D007334:Insulin-Like Growth Factor I; D013007:Growth Hormone-Releasing Hormone